Diagnosis of Sleep Disordered Breathing in Adults and Children
Customize your policy alerts
Sign up for Mass General Brigham Health Plan Policy SLP012013 alerts
Get alerted when Policy SLP012013 changes without checking for updates manually.
Monitor payer policy activity
Guideline for diagnostic evaluation and testing (PSG and HSAT) for suspected sleep-disordered breathing in adults and children, including site-of-service selection and indications for attended vs unattended testing. Applies to Mass General Brigham Health Plan members.
Divided the MCG into two separate sections for adults and children and added/expanded pediatric testing indications.
Modified HNS implantation diagnostic testing criterion to permit either PSG or HSAT performed for determining HNS candidacy without requiring PSG within the last 24 months.
Updated Medicare Advantage, DSNP, and Managed Medicaid coverage language noting lack of LCDs for Massachusetts and use of policy guidelines.
Removed the word 'Acute' from comorbid medical conditions across multiple testing sections to avoid implying cardiac arrhythmia must be acute.
Added several pediatric indications including evaluation of hypersomnia, suspected narcolepsy (with MSLT), restless leg syndrome, and periodic limb movement disorder.
Medical Necessity and Coverage Criteria
HSAT (unattended) medical necessity
HSAT meets medical necessity when ALL of the following are met:
See policy Signs and Symptoms section for symptom details
Policy lists comorbid and concomitant disorder exclusions for HSAT candidacy
Ordering clinician discretion; HSAT may be administered over multiple nights with aggregated reporting
HSAT candidacy limited to adults per policy
Attended PSG medical necessity
Attended PSG (95808, 95810) meets medical necessity when A and B, A and C, or D are present:
See Signs and Symptoms section
Policy provides a detailed comorbidity list
No minimum HSAT recording time required for diagnostic consideration
These conditions necessitate in-lab physiology and attended monitoring
Attended PAP titration medical necessity
Full-night attended PAP titration (95811) meets medical necessity when A and B, A and C, or A and D are met:
Definition of significant OSA provided in policy
Oxygen desaturation thresholds specified in policy
See policy comorbidity list (COPD/ILD, severe asthma on steroids/biologics, heart failure, pulmonary hypertension, neuromuscular disease, uncontrolled arrhythmias, chronic opioids, obesity hypoventilation)
APAP failure and adherence definitions are in policy
Split-night PSG medical necessity
Split-night study (95811) meets medical necessity when A and B, A and C, or A and D are present:
See Signs and Symptoms section
Comorbidity list in policy
No minimum HSAT recording time required
Policy lists these secondary disorders
Facility-based split night sleep study (95811)
Meets medical necessity when patient presents with (A and B) or (A and C) or (A and D):
B
- B-detail: Any one of the listed comorbid conditions
No minimum HSAT recording time required for diagnostic consideration.
Repeat diagnostic PSG/HSAT/Split Night
Covered when previously stated criteria for testing are met and at least ONE of the following:
Note: CPT 95811 is not appropriate coding for oral appliance adjustment.
Repeat attended PAP titration (95811)
Meets medical necessity for known OSA when (1 AND 2) OR 3 are met:
PAP adherence definition provided in policy
Physician attestation accepted if prior diagnostic test unavailable
Multiple Sleep Latency Test (MSLT) (95805)
Meets medical necessity when previous evaluation has not demonstrated OSA in setting of persistent excessive daytime sleepiness AND one of the following:
MSLT should be performed when fully rested and follows facility-based PSG (95810) or in-lab titration (95811); not after split-night
Maintenance of Wakefulness Test (MWT) (95805)
Meets medical necessity to evaluate response to treatment or when inability to stay awake is a safety issue.
Diagnostic testing for Hypoglossal Nerve Stimulation (HNS) implantation (Adults)
Attended sleep study (PSG or HSAT) is medically necessary prior to HNS implantation when ALL criteria are met:
Post-implant PSG required for device titration; subsequent retesting if insufficient response, substantial weight gain, or recurrent narcolepsy-like symptoms
Diagnostic testing for HNS implantation in adolescents with Down syndrome (13–18)
Attended in-lab full-night diagnostic PSG is medically necessary prior to HNS implantation when ALL criteria are met:
For adolescents with Down syndrome aged 13–18 years; post-implant PSG required for titration and further PSG for insufficient response or substantial weight change
Actigraphy
Covered as a one-time service to evaluate sufficient sleep and sleep-wake schedules prior to MSLT.
Actigraphy alone is not medically necessary to diagnose OSA
Pediatric in-facility polysomnography and titration
PSG (95782, 95808, 95810) meets medical necessity for any of the listed pediatric indications; pediatric titration meets criteria when specified conditions are met:
Policy lists comprehensive pediatric indications
Pediatric split night and re-titration requirements detailed in policy
HNS implantation diagnostic criteria (adolescents 13-18 with Down syndrome)
Covered when ALL of the following are met
For adolescents with Down syndrome aged 13–18 years.
Post-implantation polysomnography
Covered when ANY of the following are met for post-implant PSG
Initial post-implant titration PSG indicated; subsequent retesting only for listed reasons.
HSAT vs PSG site-of-care criteria
Coverage stance for diagnostic testing site of care
Evidence summary references AASM/AHRQ guidance supporting risk-stratified site selection
Coverage modifications and pediatric expansions
Key coverage-related modifications and pediatric additions
Policy modified to allow HSAT as alternative to PSG for HNS candidacy
Pediatric in-facility titration reorganized into initial full-night and full-night re-titration sections
Program exceptions and adjudication guidance added
Attended polysomnography (PSG) or home sleep apnea testing (HSAT) is not medically necessary for evaluations when the patient lacks symptoms or signs suggestive of a sleep disorder. Examples include chronic lung disease in the absence of sleep-disorder symptoms, circadian rhythm disorders, transient or chronic insomnia, restless leg syndrome, seizures without sleep-disorder symptoms, psychiatric disorders alone, snoring without evidence of excessive daytime sleepiness, screening of asymptomatic patients, and testing solely required by an employer or regulatory agency when the patient has no symptoms of excessive daytime somnolence or other signs of OSA.
Actigraphy is covered only as a one-time service to document sleep-wake schedules and sufficient sleep prior to Multiple Sleep Latency Testing (MSLT) and should include at least 7 days of monitoring. However, actigraphy when used alone to diagnose obstructive sleep apnea is not medically necessary. Other related technologies and limited studies (e.g., acoustic pharyngometry, SNAP testing with fewer than 3 channels) are also considered not medically necessary or experimental for diagnosing OSA.
Diagnostic testing performed solely to meet Commercial Driver's License (CDL) or other government/occupational licensing requirements (CPT 95808, 95810, 95811) is not medically necessary unless the patient independently meets the clinical criteria in this guideline for in‑facility or home testing.
The following diagnostic tests and procedures are considered not medically necessary or experimental for routine diagnosis of obstructive sleep apnea: actigraphy alone for OSA diagnosis; acoustic pharyngometry; SNAP testing with fewer than 3 channels; cephalographic x-rays for general OSA diagnosis (except when specifically required for oral appliance planning or surgical evaluation); x-rays of the temporomandibular joint or sella turcica; laryngeal function studies; sonography; static charge sensitive bed; tomographic x-ray; and limited daytime PAP-acclimatization studies (e.g., brief 'PAP‑nap' procedures).
The policy update removed references that are not applicable to the diagnosis of sleep‑disordered breathing and that are older than 10 years, except where retained for historical or contextual purposes. This change was part of a broader annual review and terminology clarification (for example, removing the term 'acute' from several comorbid condition listings).
Portable monitoring devices that measure fewer than 3 channels do not meet the definition of medical necessity because they provide limited physiologic information. In addition, HSAT is not medically necessary to monitor PAP efficacy in patients already diagnosed with OSA; PAP device downloads should be used for treatment monitoring and efficacy assessment.
Additional diagnostic tests listed as not medically necessary or experimental include those enumerated in the exclusions (see prior paragraphs) and certain attended ventilatory studies. Specifically, CPT 95807 (attended ventilation/ventilatory study) and the other tests described (e.g., SNAP <3 channels, acoustic pharyngometry, select x‑rays and specialty imaging) are identified as not medically necessary in most diagnostic contexts.
Specific tests called out as not medically necessary in most diagnostic circumstances include actigraphy alone for OSA diagnosis and CPT 95807 (attended ventilation/ventilatory study). The policy lists other technologies and imaging studies (see exclusions) that lack sufficient validation for routine OSA diagnosis and therefore may be denied on medical‑necessity review.
Covered and Referenced Codes, Key Thresholds
| E0601 | Auto-titrating positive airway pressure (APAP) device |
| 95811 | Split night sleep study / PAP titration (facility-based) |
| 95810 | Facility-based diagnostic polysomnography (PSG) |
| 95805 | MSLT / Maintenance of Wakefulness Test (per document uses 95805 for MSLT and MWT references) |
| 95803 | Actigraphy |
| 95782 | Pediatric in-facility PSG (referenced) |
| 95783 | Pediatric full night PAP titration / re-titration |
| 95808 | Limited-channel sleep study (referenced for CDL testing) |
| 95782 | Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist. |
| 95783 | Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi- level ventilation, attended by a technologist. |
| 95800 | Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis, and sleep time. |
| 95801 | Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis. |
| 95803 | Actigraphy testing, recording, analysis, interpretation, and report (minimum 72 hours to 14 days). |
| 95805 | Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation. |
| 95806 | Sleep study, unattended, simultaneous recording of heart rate, oxygen saturation, respiratory airflow, and respiratory effort. |
| 95807 | Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist (Not medically necessary). |
| 95808 | Polysomnography; any age, sleep staging with 1–3 additional parameters, attended by a technologist. |
| 95810 | Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters, attended by a technologist. |
| 95811 | Referenced in policy as CPT for attended PAP titration/full-night titration (oxygen saturation requirements updated previously). |
Prior Authorization, Documentation, and Provider Requirements
Prior authorization required for PSG, titration, and limited HSAT/APAP uses
Attended facility-based polysomnography (CPT 95808, 95810) and attended full‑night PAP titration (CPT 95811) require prior authorization and are covered only when the policy’s clinical criteria for medical necessity are met; unattended HSAT and unattended APAP titration (E0601) are allowed only under the conditions specified in the policy (APAP allowed when attended‑titration criteria B–D are not present).
Require PSG (or permitted HSAT) prior to HNS implantation
For hypoglossal nerve stimulation (HNS) candidates, an attended diagnostic sleep study is required for pre‑implant testing: a PSG or, in some cases as allowed by the policy, an HSAT performed for HNS candidacy that documents AHI/REI and event type per the HNS criteria.
- Adults: PSG or HSAT performed for the purpose of determining HNS candidacy is required and must demonstrate predominantly obstructive events and AHI 15–65.
- Adolescents with Down syndrome (13–18): in‑lab full‑night PSG is required and must document AHI/REI >10 and <50 along with other pre‑implant criteria.
Prior authorization and codes subject to review/frequency limits
Certain sleep study and home sleep test CPT/HCPCS codes are subject to medical necessity review, frequency limits, and prior authorization per plan rules; submit requests when frequency limits are exceeded or when tests are otherwise suspect for non‑medical necessity.
Program exceptions and adjudication for MA/DSNP/Managed Medicaid
Program exceptions and adjudication guidance apply for Medicare Advantage/DSNP and Managed Medicaid: Medicare criteria are used for DSNP members, and if a DSNP request is not fully approved under Medicare criteria the policy guidelines beginning on page one are used; managed Medicaid follows the guidelines beginning on page one.
- Massachusetts jurisdiction has no applicable LCDs; NCD 240.4.1 is not fully established locally, so the policy guidelines are used.
- Program Exceptions section added to clarify adjudication for MA/DSNP/Managed Medicaid.
Titration step therapy—attended titration after diagnosis or APAP failure
A full‑night attended PAP titration (CPT 95811) is appropriate after diagnostic confirmation of significant OSA or when an APAP trial has failed; unattended APAP titration is acceptable only if attended‑titration criteria B–D are absent.
- Titration criteria require prior diagnostic PSG or HSAT showing significant OSA (AHI/RDI/REI ≥15 or 5–14 with qualifying clinical evidence).
- APAP failure is defined by residual AHI ≥5 despite objective adherence (≥4 hours/night on 70% of nights over 30 consecutive days), residual symptoms despite adherence, intolerance after a ≥1‑month trial, or not a candidate for auto bi‑level therapy.
Document CPAP failure or intolerance before HNS
Before HNS implantation, document CPAP failure or intolerance: CPAP failure is AHI >15 despite CPAP use; CPAP intolerance is <4 hours/night on 5 nights/week or return of the device—this documentation is required for HNS candidacy.
- Include objective CPAP download showing usage or evidence the device was returned.
- Shared decision‑making documentation with a sleep expert should be included per HNS criteria.
PAP therapy trial (≥1 month) required and documented before HNS
Candidates for hypoglossal nerve stimulation must have documented failure or intolerance of PAP therapy after at least a one‑month trial prior to implantation; include objective adherence data or device return evidence.
- Adolescents with Down syndrome require documented failure/intolerance of PAP after ≥1 month as part of pre‑implant criteria.
- Adults require documentation of CPAP failure (AHI >15 on CPAP) or CPAP intolerance (<4 hours/night, 5 nights/week or returned device).
N/A
N/A
Ordering and reporting requirements—qualified ordering and interpretation
Order diagnostic sleep testing only by a licensed physician or advanced practice provider; testing must be reviewed and interpreted by a board‑certified sleep physician and HSAT results aggregated into a single report when administered over multiple nights.
- Portable monitoring devices must measure ≥3 channels; devices with fewer than 3 channels do not meet medical necessity.
- HSAT administered over multiple nights should be combined into one report and treated as one diagnostic test.
Accept physician attestation when prior study unavailable
If the previous diagnostic or baseline sleep study is not available, a physician attestation confirming the diagnosis of OSA will be accepted to support requests for repeat testing or replacement PAP therapy/supplies.
- Physician attestation may be used to determine sleep study type and to support replacement PAP/supplies when prior studies are unavailable.
- Sleep studies performed outside the U.S. are accepted if the report contains sufficient data to determine medical necessity.
Required documentation to support services beyond frequency limits
To support medical necessity for services beyond stated frequency limits, submit physician history and physical, physician procedure note, treatment plan, plan of treatment, EEG study, and prior polysomnography or sleep study reports.
- Sleep testing is limited to two (2) in 12 months; 95805 limited to one (1) day in 12 months—exceeding services require documented justification and the items above.
- Documentation should demonstrate why additional testing is medically necessary (e.g., invalid prior test, multiple sleep disorders, insufficient prior titration).
Pre‑implantation documentation required for HNS candidacy
Pre‑implantation documentation for HNS candidates must include evaluation by a board‑eligible/certified sleep physician (or consultation), pre‑implant diagnostic PSG (or permitted HSAT per policy), AHI/REI documentation, evidence adenotonsillectomy is contraindicated/ineffective (adolescents), and documentation of failed/intolerant PAP after ≥1 month plus drug‑induced sleep endoscopy when required.
- Adolescents with Down syndrome require in‑lab full‑night PSG, AHI/REI >10 and <50, and drug‑induced sleep endoscopy demonstrating absence of complete concentric palatal collapse.
- Post‑implant PSG is required for device titration and subsequent retesting if clinical response is insufficient or with substantial weight change.
Provide PSG or HSAT performed specifically for HNS candidacy
Provide a PSG or HSAT performed for the purpose of determining HNS candidacy; the policy no longer requires PSG within the last 24 months and explicitly allows HSAT in some circumstances for candidacy testing.
- Policy revision modified HNS candidacy testing to permit PSG or HSAT performed for candidacy without strict 24‑month PSG requirement.
- Ensure the test documents AHI/REI and predominance of obstructive events as required by HNS criteria.
Unsupported use: overnight oximetry alone risks denial
Overnight oximetry alone does not meet the definition of medical necessity for screening or diagnosis of OSA and may result in denial if submitted as the diagnostic test for suspected OSA.
- Use PSG or HSAT per policy criteria for diagnostic evaluation; portable devices with <3 channels are not medically necessary for diagnosis.
- Actigraphy alone is also not a valid diagnostic method for OSA.
CDL/government license testing is not medically necessary without clinical indication
Diagnostic testing performed solely for CDL or other government licensing (CPT 95808, 95810, 95811) is not medically necessary unless the patient meets the policy’s clinical criteria for in‑facility or home testing.
- Ensure clinical indications meet policy criteria before ordering testing for licensing purposes to avoid denial.
Tests identified as not medically necessary—risk of denial
Tests considered not medically necessary include actigraphy when used alone, acoustic pharyngometry, SNAP testing with fewer than 3 channels, cephalographic x‑rays except specified uses, laryngeal function studies, sonography, static charge sensitive bed, tomographic x‑ray, and limited daytime 'PAP‑nap' studies; submitting these for OSA diagnosis may trigger denial.
- CPT 95807 (limited daytime attended ventilation/ventilatory study) is identified as not medically necessary in most diagnostic contexts.
- Lateral cephalographic x‑rays may still be medically necessary for oral appliance evaluation or surgical planning per policy exceptions.
Medicare/DSNP adjudication guidance
For Medicare Advantage or DSNP members, requests not approved under Medicare criteria may be adjudicated using the policy guidelines beginning on page 1; the policy clarifies lack of applicable LCDs for Massachusetts and the use of the policy for adjudication.
- DSNP members: Medicare coverage criteria are applied first; if not fully approved, the standard policy guidelines are used.
- Managed Medicaid members: the guidelines beginning on page 1 are used for adjudication.
Key Definitions and Device Classifications
Background: Sleep studies—either attended in‑lab polysomnography (PSG) or unattended home sleep apnea testing (HSAT)—are used to diagnose sleep disorders and to assess treatment effectiveness. Initial diagnostic testing is appropriate for patients at increased risk of moderate to severe obstructive sleep apnea, typically identified by witnessed apneas or a combination of excessive daytime sleepiness and signs of sleep‑disordered breathing; the guideline clarifies site‑of‑care selection and indications for attended versus unattended testing.
Policy Changes and Revision Notes
Policy reorganized adult and pediatric diagnostic sections; allowed PSG or HSAT for HNS candidacy (removed strict 24-month PSG-only requirement); expanded pediatric testing indications and reorganized pediatric titration sections.
Program EXCEPTIONS were added and Medicare Advantage/DSNP/Managed Medicaid adjudication language clarified (noting lack of LCDs for Massachusetts and guidance for DSNP adjudication).
Removed the word 'Acute' from comorbid medical conditions across multiple testing sections to acknowledge arrhythmias may be acute or chronic.
Expanded pediatric indications to include evaluation of hypersomnia, suspected narcolepsy (with MSLT), restless leg syndrome, and periodic limb movement disorder.
References were reviewed and updated, incorporating recent high-level evidence and removing older references not required for context.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.